WHAT IS CLAIMED IS:

1. A composition comprising between one and six intradermal doses, between one and two intratumoral doses and between five and ten intravenous doses of activated allogeneic Th1 cells with cross-linking agents that cross-link CD3 and CD28 cell surface moieties, wherein the intradermal doses comprise between 1×10^6 to 1×10^7 cells/ml, the intratumoral doses comprise between 1×10^7 to 1×10^8 cells/ml and the intravenous doses comprise between 1×10^7 to 1×10^9 cells/ml, respectively, wherein the cross-linking agents are immobilized on surface of biodegradable beads and wherein the Th1 cells, the cross-linking agents and the biodegradable beads are suspended in a non-nutrient media.

2. The composition of claim 1, wherein the composition comprises between three and six intradermal doses, between one and two intratumoral doses and between six and nine intravenous doses, respectively.

3. The composition of claim 1 where the activated Th1 cells secrete one or more of the following Th1 cytokines: IL-2, IFN-gamma and GM-CSF.

4. The composition of claim 3 where the activated Th1 cells express DC maturation molecule CD40L and/or FasL on their surface.

5. The composition of claim 1 where the doses of Th1 cells are packaged in a syringe.

6. The composition of claim 1 wherein the cross-linking of CD3 and CD28 is through anti-CD3 and anti-CD28 monoclonal antibodies.